Multi-organ media compositions and methods of their use

Patent metadata

Field	Value
Publication number	US-10564148-B2
Application number	US-201515513948-A
Country	US
Kind code	B2
Filing date	Sep 24, 2015
Priority date	Sep 24, 2014
Publication date	Feb 18, 2020
Grant date	Feb 18, 2020

Abstract

Disclosed herein are media for culture of cells, tissues, and/or organs. The media formulations disclosed herein can be used to support growth, viability, and/or function of one or more than one cell type, tissue, or organ. In some embodiments, one or more cell types, tissues, organ devices, and/or organs are contacted with a disclosed culture medium under conditions sufficient to support growth, viability, and/or function of the cell types, tissues, and/or organs. The disclosed media can be used in methods of culturing multiple cell types, and in some examples, is used in a platform device including one or more organ devices, for example, by circulating the medium through the one or more organ devices in the platform.

First claim

We claim:

1. A system comprising:
(a) a cell or tissue culture medium comprising an aqueous solution comprising 92.0 mM NaCl, 3.43 mM KCl, 1.00 mM CaCl 2 .2H 2 O, 0.453 mM NaH 2 PO 4 , 0.407 mM MgSO 4 , 0.696 nM ZnSO 4 .7H 2 O, 0.248 nM Fe(NO 3 ) 3 .9H 2 O, 0.699 mM L-arginine, 0.450 mM L-leucine, 0.415 mM L-isoleucine, 0.250 mM glycine, 0.215 mM L-phenylalanine, 0.0499 mM L-alanine, 0.0500 mM L-asparagine, 0.250 mM L-serine, 0.221 mM L-valine, 0.150 mM L-histidine, 0.150 mM L-proline, 0.0442 mM L-tryptophan, 0.116 mM L-methionine, 0.301 mM L-lysine, 0.0500 mM L-glutamic acid, 0.998 mM L-cysteine, 0.227 mM sodium pyruvate, 0.0165 mM niacinamide/nicotinamide, 0.0111 mM myoinositol/inositol, 0.0107 mM choline chloride, 9.71 μM pyridoxine, 6.43 μM thiamine, 2.27 μM folic acid, 2.10 μM D-calcium pantothenate, 0.148 μM vitamin B-12, 0.133 μM riboflavin, 0.0143 μM D-biotin, 14.3 mM sodium bicarbonate, 0.499 μM DL-6,8-thioctic acid/lipoic acid, 0.125 mg/L transferrin, 0.360 mg/L CuSO 4 .5H 2 O, and 0.0380 nM Na 2 SeO 3 ; and
(b) (i) primary cells or tissue wherein the primary cells or tissue comprises one or more kidney, liver, or lung cells or tissue; or
(ii) one or more organ devices, which comprises a kidney, liver, or lung organ device or a combination thereof,

wherein the cell or tissue culture medium contacts the primary cells, tissue, or organ device in vitro.

2. The system of claim 1 , wherein the cell or tissue culture medium further comprises an aqueous solution comprising 0.500 mM Na 2 HPO 4 , 1.50 μM FeSO 4 .7H 2 O, 0.301 nM MgCl 2 , 0.0150 mM L-aspartic acid, 0.0168 mM L-tyrosine disodium, 0.684 mM L-alanyl-L-glu, 2.00 mM L-glutamine, 0.449 mM L-threonine, 0.199 mM L-tyrosine disodium salt dihydrate, 0.100 mM L-cystine, 2.78 mM D-fructose, 5.55 mM D-galactose, 5.49 mM D-sorbitol, 1.00 mM sodium acetate anhydrous, 0.0900 mM adenine, 0.252 μM vitamin D 2 , 0.0164 mM Na 2 EDTA.H 2 O, 0.546 μM D-pantothenic acid hemicalcium, 0.497 μM putrescine, 0.546 μM pyridoxal, 0.0212 μM L-tocopherol acetate, 1.51 μM thymidine, 0.304 μM vitamin A acetate, 0.989 mM sodium propionate, 0.150 μM linoleic acid, 0.0170 μM methyl linoleate, 0.0164 mM arachidonic acid, 8.97 μM penicillin, 2.20 μM xanthine, 0.861 nM insulin, 0.0376 μM bovine serum albumin, 0.0100 μM VEGF, 1.00 nM bFGF, 0.100 nM triiodothyronine, 11.3 mM HEPES free acid, 0.0150 mM polyoxyethylene 20 sorbitan monooleate, 0.0133 mM hypoxanthine, 2.70 μM uracil, 0.0999 μM retinoic acid, 0.500 nM EGF, 0.0370 μM hydrocortisone, 8.19 nM ethanolamine, 0.861 nM glucagon, 0.0100 g/L bovine pituitary extract, 1.00 μM epinephrine, 0.500 μM phosphorylethanolamine, 0.0500 mM silicon, 1.71 nM vanadium, 1.14 nM manganese, 0.100 μM molybdenum, 0.100 μM NiSO 4 , 3.10 nM tin, 2.87 nM GeO 2 , 2.47 nM CrK(SO 4 ) 2 , 6.00 nm AlCl 3 , 1.14 nM MnCl 2 , 0.482 nM KI, 0.421 nM NiCl 2 , 0.210 nM KBr, 0.207 nM Na 2 MoO 4 , 0.0331 nM RbCl, 0.0209 nM AgCl, and 8.41 pM CoCl 2 .

3. A method of culturing one or more cell types, one or more tissues, or one or more organs, comprising incudbating the system of claim 2 under conditions sufficient to maintain the viability, function, and/or growth of the one or more cells, tissue, or organ devices, wherein the one or more cell or tissue types comprise one or more primary heart cell or tissue types, or wherein the one or more organ devices comprise a kidney, liver, or lung organ device.

4. The cell or tissue culture medium of claim 1 , further comprising glucose.

5. A system, comprising:
(a) a cell or tissue culture medium comprising an aqueous solution comprising 106 mM NaCl, 4.76 mM KCl, 1.63 mM CaCl 2 .2H 2 O, NaH 2 PO 4 , 0.609 mM MgSO 4 , 0.750 μM ZnSO 4 .7H 2 O, 0.0620 μM Fe(NO 3 ) 3 .9H 2 O, 0.250 mM Na 2 HPO 4 , 0.750 μM FeSO 4 .7H 2 O, 0.151 mM MgCl 2 , 1.53 mM L-aspartic acid, 1.78 mM L-arginine, 1.48 mM L-leucine, 1.46 mM L-isoleucine, 1.13 mM glycine, 1.11 mM L-phenylalanine, 1.02 mM L-alanine, 0.805 mM L-tyrosine disodium, 0.775 mM L-asparagine, 0.625 mM L-serine, 0.610 mM L-valine, 0.575 mM L-histidine, 0.575 mM L-proline, 0.342 mM L-alanyl-L-glu, 0.272 mM L-tryptophan, 0.209 mM L-methionine, 0.400 mM L-lysine, 0.175 mM L-glutamic acid, 0.118 mM L-cysteine, 1.28 mM L-glutamine, 0.225 mM L-threonine, 0.107 mM L-tyrosine disodium salt dihydrate, 0.0500 mM L-cystine, 1.51 mM sodium pyruvate, 1.39 mM D-fructose, 2.78 mM D-galactose, 2.75 mM D-sorbitol, 0.500 mM sodium acetate anhydrous, 0.0492 mM niacinamide/nicotinamide, 0.0406 mM myoinositol/inositol, 0.0374 mM choline chloride, 9.79 μM pyridoxine, 6.43 μM thiamine, 4.14 μM folic acid, 3.40 μM D-calcium pantothenate, 0.325 μM vitamin B-12, 0.358 μM riboflavin, 1.03 μM D-biotin, 0.126 μM vitamin D 2 , 8.20 μM Na 2 EDTA.H 2 O, 0.252 μM putrescine, 0.273 μM pyridoxal, 0.0106 μM D,L-tocopherol acetate, 0.754 μM thymidine, 0.152 μM vitamin A acetate, 0.495 mM sodium propionate, 8.97 μM linoleic acid, 8.50 nM methyl linoleate, 8.20 μM arachidonic acid, 0 . 0850 mM penicillin, 20.2 mM sodium bicarbonate, 0.739 μM DL-6,8-thioctic acid/lipoic acid, 5.30 mg/L transferrin, 7.52 μM xanthine, 0.500 μM insulin, 0.0188 μM bovine serum albumin, 5.00 nM VEGF, 0.500 nM bFGF, 0.0500 nM triiodothyronine, 0.431 nM glucagon, 0.855 nM vanadium, 0.571 nM manganese, 1.55 nM tin, 2.78 nM CuSO 4 .5H 2 O, 1.44 nM GeO 2 , 1.24 nM CrK(SO 4 ) 2 , 3.00 nM AlCl 3 , 0.570 nM MnCl 2 , 0.241 nM KI, 0.211 nM NiCl 2 , 0.105 nM KBr, 0.104 nM Na 2 MoO 4 , 0.0160 μM Na 2 SeO 3 , 0.0166 nM RbCl, 0.0105 nM AgCl, and 4.21 pM CoCl 2 ; and
(b) (i) primary cells or tissue wherein the primary cells or tissue comprises one or more kidney, liver, or lung cells or tissue; or
(ii) one or more organ devices, which comprises a kidney, heart, liver, or lung organ device or a combination thereof,
wherein the cell or tissue culture medium contacts the primary cells, tissue, or organ device in vitro.

6. A method of culturing one or more cell types, one or more tissues, or one or more organs, comprising incubating the system of claim 5 under conditions sufficient to maintain the viability, function, and/or growth of the one or more cells, tissue, or organ devices, wherein the one or more cell or tissue types comprise one or more primary liver cell or tissue types or one or more primary heart cell or tissue types, or wherein the one or more organ devices comprise a liver or lung organ device.

7. A method, comprising perfusing the system of claim 5 , wherein the system comprises the organ device, and the organ device is fluidly coupled to a platform device comprising:
an organ perfusion system in fluid communication with a fresh media circuit and a recirculation circuit, wherein the fresh media circuit is fluidly coupled to the organ device and the recirculation circuit is fluidly coupled to the organ device;
one or more pumps capable of pumping fluid to one or more valves;
a perfusion controller in electrical communication with the organ perfusion system; and
an analyzer, a sensor, or a combination thereof in electrical communication with the perfusion controller, wherein the medium is introduced to the organ device through the fresh media circuit.

8. The method of claim 7 , wherein the platform device comprises two or more fluidly coupled organ devices.

9. The method of claim 7 , further comprising:
introducing a compound, or composition containing a compound, into the medium in the fresh media circuit; and
analyzing a response generated by the organ device after the compound, or composition thereof, has been introduced into the platform device.

10. The method of claim 9 , further comprising extracting a sample from the platform device.

11. The method of claim 10 , further comprising introducing the sample into a chromatograph, a m

Assignees

• Los Alamos Nat Security Llc
• Cfd Res Corporation
• Triad Nat Security Llc

Inventors

• Iyer Rashi
• Harris Jennifer F
• Huang Jen-Huang
• Nath Pulak
• Przekwas Andrzej

Classifications

• F16K7/045

  by electric or magnetic means · CPC title

• B01L3/502707

  characterised by the manufacture of the container or its components · CPC title

• B01L2300/123

  Flexible; Elastomeric · CPC title

• B01L2300/0832

  cylindrical, tube shaped · CPC title

• B01L3/5027

  by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip · CPC title